Results 71 to 80 of about 21,275,692 (207)
Non-Small Cell Lung Cancer in the Elderly
Abstract Learning Objectives After completing this course, the reader will be able to: Describe the difference between chronologic and biologic age in patients with NSCLC. Discuss how clinical trials establish biologic rather than chronologic age in patients with NSCLC.
Paris D, Makrantonakis +2 more
openaire +2 more sources
Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation ...
Yixuan Wang +6 more
doaj +1 more source
Nanostring nCounter targeted RNA Seq. data of fibroblast cells isolated from human non-cancerous lung tissue and non-small cell lung cancer tumour tissue as well as fibroblasts maintained for three passages in culture from both origins as shown in ...
Koppensteiner, Lilian +5 more
core +1 more source
Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer. [PDF]
The cancer stem cell hypothesis, that a small population of tumour cells are responsible for tumorigenesis and cancer progression, is becoming widely accepted and recent evidence has suggested a prognostic and predictive role for such cells. Intra-tumour
Banerji, CR +11 more
core +1 more source
Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6 [PDF]
Background: There are several perceived benefits from introducing positron emission tomography (PET) scanning into the staging of non small lung cancer (NSCLC).
Stephen Goodall +2 more
core
Immunotherapy in inoperable stage III non-small cell lung cancer: a review
The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC).
Natasha A Jain, Gregory A Otterson
doaj +1 more source
Bevacizumab in Non–Small Cell Lung Cancer [PDF]
Abstract Angiogenesis, the growth of new vessels from preexisting vessels, is a fundamental step in tumor growth and progression. Vascular endothelial growth factor (VEGF) is a key angiogenic factor implicated in tumor blood vessel formation and permeability.
openaire +2 more sources
MET Inhibition in Non-Small Cell Lung Cancer
Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life.
Shabnam Rehman, Grace K. Dy
doaj
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen +5 more
doaj +1 more source
Non-small-cell lung cancer is one of the most lethal cancers in the worldwide. Although Paclitaxel-based combinational therapies have long been used as a standard treatment in aggressive non-small-cell lung cancers, Paclitaxel resistance emerges as a ...
Yimin Lu +6 more
doaj +1 more source

